Nectar Lifesciences (NSE:NECLIFE) Total Operating Expense: ₹1,570 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
50 GF Score
Price ₹10.30
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences Total Operating Expense?

Nectar Lifesciences NSE:NECLIFE -0.58% 50 Total Operating Expense is ₹1,570 Mil as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 50/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Nectar Lifesciences's Total Operating Expense for the three months ended in Mar. 2026 was ₹573 Mil. Nectar Lifesciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,570 Mil.

Nectar Lifesciences Total Operating Expense Related Terms

Nectar Lifesciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Total Operating Expense Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,977.28 1,974.18 2,048.24 7.81 590.34

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 955.35 21.75 19.87 573.18
NSE:NECLIFE
50GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,570 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹1,570 Mil mean?
Nectar Lifesciences (NSE:NECLIFE) has a Total Operating Expense of ₹1,570 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' Total Operating Expense too high?
Nectar Lifesciences' current Total Operating Expense is ₹1,570 Mil. Overall, Nectar Lifesciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Total Operating Expense compare to ZTS and UTHR?
Nectar Lifesciences' Total Operating Expense of ₹1,570 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current Total Operating Expense is ₹1,570 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹10.30 — trading 50.1% above its estimated fair value. The current Total Operating Expense is ₹1,570 Mil. Nectar Lifesciences' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Total Operating Expense is ₹1,570 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹10.30 is trading 50.1% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Total Operating Expense: ₹1,570 Mil
  • GF Value™: ₹6.86 vs. price of ₹10.30 (50.1% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
50GF Score

Get the complete analysis for NSE:NECLIFE

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.30
Price
₹6.86
GF Value